RPG Investment Advisory LLC Sells 568 Shares of Jazz Pharmaceuticals PLC (JAZZ)

Share on StockTwits

RPG Investment Advisory LLC reduced its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 4.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,960 shares of the specialty pharmaceutical company’s stock after selling 568 shares during the period. RPG Investment Advisory LLC’s holdings in Jazz Pharmaceuticals were worth $1,710,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Kornitzer Capital Management Inc. KS boosted its position in shares of Jazz Pharmaceuticals by 0.5% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 17,378 shares of the specialty pharmaceutical company’s stock valued at $2,154,000 after acquiring an additional 85 shares in the last quarter. First Hawaiian Bank boosted its position in Jazz Pharmaceuticals by 42.2% in the fourth quarter. First Hawaiian Bank now owns 320 shares of the specialty pharmaceutical company’s stock valued at $39,000 after buying an additional 95 shares in the last quarter. Advisor Group Inc. boosted its position in Jazz Pharmaceuticals by 3.3% in the fourth quarter. Advisor Group Inc. now owns 3,755 shares of the specialty pharmaceutical company’s stock valued at $465,000 after buying an additional 120 shares in the last quarter. Comerica Bank boosted its position in Jazz Pharmaceuticals by 1.0% in the fourth quarter. Comerica Bank now owns 12,103 shares of the specialty pharmaceutical company’s stock valued at $1,512,000 after buying an additional 123 shares in the last quarter. Finally, ETF Managers Group LLC boosted its position in Jazz Pharmaceuticals by 18.3% in the fourth quarter. ETF Managers Group LLC now owns 881 shares of the specialty pharmaceutical company’s stock valued at $109,000 after buying an additional 136 shares in the last quarter. Institutional investors and hedge funds own 93.41% of the company’s stock.

In other Jazz Pharmaceuticals news, EVP Suzanne Sawochka Hooper sold 6,666 shares of the business’s stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $140.00, for a total value of $933,240.00. Following the completion of the transaction, the executive vice president now directly owns 40,401 shares of the company’s stock, valued at $5,656,140. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Matthew P. Young sold 1,916 shares of the business’s stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $131.46, for a total transaction of $251,877.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,668 shares of company stock valued at $1,606,567. Insiders own 3.90% of the company’s stock.

JAZZ has been the topic of a number of recent analyst reports. Cowen restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 13th. Cantor Fitzgerald restated a “buy” rating and issued a $185.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, February 12th. Wells Fargo & Co restated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Sunday, December 23rd. Oppenheimer set a $180.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, December 23rd. Finally, BidaskClub upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, December 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $184.53.

Shares of NASDAQ JAZZ traded up $1.27 during trading on Monday, reaching $138.39. The company had a trading volume of 356,876 shares, compared to its average volume of 674,135. Jazz Pharmaceuticals PLC has a 52 week low of $113.52 and a 52 week high of $184.00. The company has a market cap of $7.82 billion, a PE ratio of 11.31, a P/E/G ratio of 0.93 and a beta of 1.23. The company has a current ratio of 3.57, a quick ratio of 3.42 and a debt-to-equity ratio of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $3.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.66 by $0.61. Jazz Pharmaceuticals had a net margin of 23.64% and a return on equity of 26.20%. The company had revenue of $476.46 million during the quarter, compared to the consensus estimate of $459.48 million. During the same period in the previous year, the firm posted $2.95 earnings per share. The company’s revenue was up 9.2% on a year-over-year basis. As a group, equities research analysts forecast that Jazz Pharmaceuticals PLC will post 13.19 earnings per share for the current year.

WARNING: This news story was published by Macon Daily and is the sole property of of Macon Daily. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://macondaily.com/2019/04/15/rpg-investment-advisory-llc-sells-568-shares-of-jazz-pharmaceuticals-plc-jazz.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Story: What Are Treasury Bonds?

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.